Overview

Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's or SLE

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Swedish Orphan Biovitrum